Recent Finacing
Recent Raise
Cleara develops FOXO4-based D‑amino‑acid peptide therapies and biomarkers to selectively eliminate scarred senescent cells in late-stage cancers, advancing two preclinical leads with favorable PK and model efficacy.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at CLEARA.
